Citations

Showing 10 of 108152 citations.

Endovascular Coil Embolization of a Posterior Communicating Artery Aneurysm: 2-Dimensional Operative Video
Darwal, Maureen A, Hakma, Zakaria, Binning, Mandy J., Bain, Mark, Bendock, Bernard, Boulos, Alan S. , Crowley, Webster, Fessler, Richard D., Guterman, Lee R., Hoit, Daniel , Hopkins, L. Nelson , Howington, Jay U., James, Robert F. , Jankowitz, Brian T. , Kan, Peter , Khalessi, Alex A, Kim, Louis J. , Langer, David J. , Mack, William J. , Mericle, Robert A., Ogilvy, Chris, Replogle, Robert, Riina, Howard A. , Saugaveau, Eric, Schirmer, Clemens M. , Spiotta, Alex, Sultan, Ali, Turner, Raymond, Veznedaroglu, Erol, Welch, Babu G. , White, Jonathan, Schirmer, Clemens M , Arthur, Adam Stephen , Grande, Andrew Walker , Hanel, Ricardó A. , Kim, Louis J. , Lanzino, Giuseppe , Levitt, Michael R. , Levy, Elad I. , Lopes, Demetrius K. , Mocco, J , Pandey, Aditya S , Ringer, Andrew J. , Rodriguez, Rafael, Siddiqui, Adnan H. , Tawk, Rabih G. , Thomas, Ajith J , White, Jonathan A.

Mayo Clinic

Operative Neurosurgery | August 12, 2021 | Volume: 19 | Issue: 6 | Pages: E597-E598

10.1093/ons/opaa278 | PMID 34383933 Get It

Abstract Since the International Subarachnoid Aneurysm Trial, 1 endovascular treatment has been the favored treatment for appropriate ruptured intracranial aneurysms. While our endovascular technology has advanced to allow us to treat the majority of intracranial aneurysms, simple coil embolization is still the most common modality. This video demonstrates the fundamentals of aneurysm catheterization and coiling for safe treatment. In addition, the set-up and devices are detailed. This video is to add to the library of basic techniques that will aid a large number of practitioners. This patient consented to endovascular treatment. The video demonstrates endovascular coil embolization of a posterior communicating artery aneurysm in a 76-yr-old female who presented with a subarachnoid hemorrhage. Image of biplane suite in video used courtesy of Siemens Medical Solutions USA, Inc. Illustration at 5:12 reprinted from Yasargil MG, et al, Microneurosurgery IV B , p. 9, Thieme, New York, 1995.
Case presentation and panel discussion: Critical illness
Mundi, Manpreet S. , Patel, Jayshil J. , Mechanick, Jeffrey I. , Arabi, Yaseen M. , Alverdy, John C. , Puthucheary, Zudin , McClave, Stephen A. , Mechanick, Jeffrey I. , Mundi, Manpreet S , Patel, Jayshil J , McClave, Stephen A , Arabi, Yaseen M

Mayo Clinic

Journal of Parenteral and Enteral Nutrition | August 12, 2021 | Volume: 45 | Issue: S2 | Pages: No page available

10.1002/jpen.2250 | PMID 34383970 Get It

AbstractDespite a mounting evidentiary base, controversies surrounding critical care nutrition support persist. Anchored by a case of a 60‐year‐old male with esophageal cancer who develops acute hypoxemic respiratory failure and septic shock, five panelists from the American Society of Parenteral and Enteral Nutrition (ASPEN) 2021 Pre‐Conference discuss key clinical dilemmas in critical care nutrition, including hierarchy of evidence, bedside evaluation of malnutrition, optimal protein dose, use of fiber, and therapies targeting gut function and gut microbiota .
Functional mitral regurgitation: a proportionate or disproportionate focus of attention?
Benfari, Giovanni , Messika–Zeitoun, David , Grigioni, Francesco , Enriquez-Sarano, Maurice , Benfari, Giovanni , Messika-Zeitoun, David , Enriquez‐Sarano, Maurice , Michelena, Héctor I. , Grigioni, Francesco

Mayo Clinic

European Journal of Heart Failure | August 12, 2021 | Volume: 23 | Issue: 10 | Pages: 1759-1762

10.1002/ejhf.2330 | PMID 34383994 Get It

Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer
Francini, Edoardo , Ou, Fang‐Shu , Wolfe, Eric, O’Connor, Edward , Gydush, Gregory, Kelleher, Kaitlin M. , Bhatt, Rupal S. , Balk, Steven P. , Sweeney, Christopher J. , Adalsteinsson, Viktor A. , Taplin, Mary‐Ellen , Choudhury, Atish D. , Wolfe, Eric G, Balk, Steven , Choudhury, Atish D , Ou, Fang-Shu , Sweeney, Christopher , Rhoades, Justin , Ha, Gavin

Mayo Clinic

Cancers | August 12, 2021 | Volume: 13 | Issue: 16 | Pages: 4055

10.3390/cancers13164055 | PMID 34439209 Get It

There are no biomarkers predictive of resistance to docetaxel or cabazitaxel validated for patients with metastatic castration-resistant prostate cancer (mCRPC). We assessed the association between ABCB1 amplification and primary resistance to docetaxel or cabazitaxel for patients with mCRPC, using circulating cell-free DNA (cfDNA). Patients with ≥1 plasma sample drawn within 12 months before starting docetaxel (cohort A) or cabazitaxel (cohort B) for mCRPC were identified from the Dana–Farber Cancer Institute IRB approved database. Sparse whole genome sequencing was performed on the selected cfDNA samples and tumor fractions were estimated using the computational tool ichorCNA. We evaluated the association between ABCB1 amplification or other copy number alterations and primary resistance to docetaxel or cabazitaxel. Of the selected 176 patients, 45 samples in cohort A and 21 samples in cohort B had sufficient tumor content. No significant association was found between ABCB1 amplification and primary resistance to docetaxel (p = 0.58; odds ratio (OR) = 1.49) or cabazitaxel (p = 0.97; OR = 1.06). No significant association was found between exploratory biomarkers and primary resistance to docetaxel or cabazitaxel. In this study, ABCB1 amplification did not predict primary resistance to docetaxel or cabazitaxel for mCRPC. Future studies including ABCB1 amplification in a suite of putative biomarkers and a larger cohort may aid in drawing definitive conclusions.
Author response: CXCL10/CXCR3 signaling contributes to an inflammatory microenvironment and its blockade enhances progression of murine pancreatic precancerous lesions
Bastea, Ligia I. , Doeppler, Heike, Eisenhauer, Jillian, Le, Tam T., Edenfield, Brandy , Störz, Peter , Bastea, Ligia , Pandey, Veethika , Martinez, Alicia K. Fleming , Döppler, Heike, Le, Tam

Mayo Clinic

No container title available | August 12, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.60646.sa2 Get It

Novel Innovations for Ventricular Assist Device Infection
Polycarpou, Andreas , Pahwa, Siddharth , Stulak, John M., Blackmon, Shanda H, Blackmon, Shanda

Mayo Clinic

ASAIO Journal | August 12, 2021 | Volume: 67 | Issue: 12 | Pages: e221-e223

10.1097/mat.0000000000001546 | PMID 34380952 Get It

Device infection is a major potential complication following ventricular assist device implantation and can lead to devastating consequences. The treatment options are few and often challenging to implement. The most durable option may require device exchange to obtain adequate source control. Due to the prolonged support times offered by the new left ventricular assist devices (LVADs), there is concern that the number of patients that will eventually require repeated device exchanges for device infection will increase. The benefit of medical antibiotic therapy alone is limited and is frequently unsuccessful. Surgical treatment strategies that improve outcomes by eliminating the infection and by preventing infection recurrence are needed. We report a case of a third-time LVAD exchange (4th device implant) for device infection within eight years of the index implant, and we briefly discuss the role of the greater omentum in the surgical treatment of this complication.
COVID-19 Convalescent Plasma Is More than Neutralizing Antibodies: A Narrative Review of Potential Beneficial and Detrimental Co-Factors
Focosi, Daniele , Franchini, Massimo , Pirofski, Liise‐anne , Burnouf, Thierry , Fairweather, DeLisa , Joyner, Michael J. , Casadevall, Arturo , Fairweather, DeLisa , Casadevall, Arturo , Franchini, Massimo , Joyner, Michael J , Focosi, Daniele

Mayo Clinic

Viruses | August 11, 2021 | Volume: 13 | Issue: 8 | Pages: 1594

10.3390/v13081594 | PMID 34452459 Get It

COVID-19 convalescent plasma (CCP) is currently under investigation for both treatment and post-exposure prophylaxis. The active component of CCP mediating improved outcome is commonly reported as specific antibodies, particularly neutralizing antibodies, with clinical efficacy characterized according to the level or antibody affinity. In this review, we highlight the potential role of additional factors in CCP that can be either beneficial (e.g., AT-III, alpha-1 AT, ACE2+ extracellular vesicles) or detrimental (e.g., anti-ADAMTS13, anti-MDA5 or anti-interferon autoantibodies, pro-coagulant extracellular vesicles). Variations in these factors in CCP may contribute to varied outcomes in patients with COVID-19 and undergoing CCP therapy. We advise careful, retrospective investigation of such co-factors in randomized clinical trials that use fresh frozen plasma in control arms. Nevertheless, it might be difficult to establish a causal link between these components and outcome, given that CCP is generally safe and neutralizing antibody effects may predominate.
Role of PLEXIND1/TGFβ Signaling Axis in Pancreatic Ductal Adenocarcinoma Progression Correlates with the Mutational Status of KRAS
Vivekanandhan, Sneha , Madamsetty, Vijay Sagar , Dutta, Shamit K., Wang, Enfeng , Caulfield, Thomas R. , Pletnev, Alexandre A., Asmann, Yan W. , Chang, David K. , Spaller, Mark R., Mukhopadhyay, Debabrata , Madamsetty, Vijay S , Angom, Ramcharan Singh , Dutta, Shamit Kumar, Caulfield, Thomas R , Chang, David , Mukhopadhyay, Debabrata , Upstill-Goddard, Rosanna

Mayo Clinic

Cancers | August 11, 2021 | Volume: 13 | Issue: 16 | Pages: 4048

10.3390/cancers13164048 | PMID 34439202 Get It

PLEXIND1 is upregulated in several cancers, including pancreatic ductal adenocarcinoma (PDAC). It is an established mediator of semaphorin signaling, and neuropilins are its known coreceptors. Herein, we report data to support the proposal that PLEXIND1 acts as a transforming growth factor beta (TGFβ) coreceptor, modulating cell growth through SMAD3 signaling. Our findings demonstrate that PLEXIND1 plays a pro-tumorigenic role in PDAC cells with oncogenic KRAS (KRASmut). We show in KRASmut PDAC cell lines (PANC-1, AsPC-1,4535) PLEXIND1 downregulation results in decreased cell viability (in vitro) and reduced tumor growth (in vivo). Conversely, PLEXIND1 acts as a tumor suppressor in the PDAC cell line (BxPC-3) with wild-type KRAS (KRASwt), as its reduced expression results in higher cell viability (in-vitro) and tumor growth (in vivo). Additionally, we demonstrate that PLEXIND1-mediated interactions can be selectively disrupted using a peptide based on its C-terminal sequence (a PDZ domain-binding motif), an outcome that may possess significant therapeutic implications. To our knowledge, this is the first report showing that (1) PLEXIND1 acts as a TGFβ coreceptor and mediates SMAD3 signaling, and (2) differential roles of PLEXIND1 in PDAC cell lines correlate with KRASmut and KRASwt status.
Heart Failure with Preserved Ejection Fraction: Mechanisms and Treatment Strategies
Omote, Kazunori , Verbrugge, Frederik H. , Verbrugge, Frederik H , Borlaug, Barry A.

Mayo Clinic

Annual Review of Medicine | August 11, 2021 | Volume: 73 | Issue: 1 | Pages: 321-337

10.1146/annurev-med-042220-022745 | PMID 34379445 Get It

Approximately half of all patients with heart failure (HF) have a preserved ejection fraction, and the prevalence is growing rapidly given the aging population in many countries and the rising prevalence of obesity, diabetes, and hypertension. Functional capacity and quality of life are severely impaired in heart failure with preserved ejection fraction (HFpEF), and morbidity and mortality are high. In striking contrast to HF with reduced ejection fraction, there are few effective treatments currently identified for HFpEF, and these are limited to decongestion by diuretics, promotion of a healthy active lifestyle, and management of comorbidities. Improved phenotyping of subgroups within the overall HFpEF population might enhance individualization of treatment. This review focuses on the current understanding of the pathophysiologic mechanisms underlying HFpEF and treatment strategies for this complex syndrome.
Partial versus radical nephrectomy in clinical T2 renal masses
Tsivian, Matvey , Packiam, Vignesh T. , Lohse, Christine M. , Ahmed, Mohamed E. , Potretzke, Theodora A. , Gopalakrishna, Ajay , Boorjian, Stephen A. , Thompson, R. Houston, Leibovich, Bradley C. , Potretzke, Aaron M. , Klett, Dane E, Klett, Dane

Mayo Clinic

International Journal of Urology | August 11, 2021 | Volume: 28 | Issue: 11 | Pages: 1149-1154

10.1111/iju.14664 | PMID 34382267 Get It

Objective To report perioperative, renal functional and oncologic outcomes for patients undergoing partial or radical nephrectomy for cT2 renal masses. Methods Retrospective review of patients who underwent partial ( n = 72) or radical nephrectomy ( n = 379) for cT2 renal masses from 2000 to 2016. After propensity adjustment using inverse probability weighting, the following were compared by surgery (partial or radical nephrectomy): complications, renal function measured by estimated glomerular filtration rate as continuous and as <60 mL/min/1.73 m 2 at 1 and 3 years postoperatively and overall, metastases‐free survival and cancer‐specific survival in patients with renal cell carcinoma. Results After propensity adjustment, clinical and radiographic features were well‐balanced between groups. Overall and severe complications were more common for partial compared with radical nephrectomy, although not statistically significant (19 vs 13%, P = 0.14 and 4 vs 2%, P = 0.3, respectively). Estimated glomerular filtration rate change at 1 and 3 years was more pronounced in radical compared with partial nephrectomy (median −16 vs −5 and −14 vs −2, respectively, P < 0.001). A greater proportion of radical nephrectomy patients had an estimated glomerular filtration rate <60 at 1 and 3 years (55 vs 17% and 48 vs 17%, respectively, P < 0.01). In renal cell carcinoma patients, overall, metastases‐free and cancer‐specific survival were not significantly different between groups (median survivor follow up 7.1 years, interquartile range 3.6–11.4). Conclusions Partial nephrectomy appears to be a relatively safe and a potentially effective treatment for cT2 renal masses, conferring better renal functional preservation compared with radical nephrectomy. These data support continued use of partial nephrectomy for renal masses >7 cm in appropriately selected patients.